Synovial and Mucosal Immunopathology in Spondyloarthritis

  • Bernard Vandooren
  • Paul P. Tak
  • Dominique Baeten
Part of the Advances in Experimental Medicine and Biology book series (volume 649)


Chronic inflammation of musculoskeletal structures is the most prominent disease manifestation of SpA. More specifically, the axial disease affects the spine, the sacroiliac joints and the hips. Peripheral disease includes peripheral arthritis, with a preference for asymmetrical inflammation of joints of the lower limbs and enthesitis, which is the presence of inflammation at the sites were ligaments and tendons attach to the bone. Additionally, SpA is often characterized by subclinical inflammation of the gut which partially resembles inflammatory bowel disease.1 Here, we will review the immunopathology of these different disease manifestations and relate them to clinical applications as well as emerging pathogenic concepts.


Ankylose Spondylitis Synovial Membrane Unfold Protein Response Sacroiliac Joint Serum MMP3 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006; 20(3):451–71.PubMedGoogle Scholar
  2. 2.
    Cawley MI, Chalmers TM, Kellgren JH et al. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis 1972; 31:345–58.PubMedGoogle Scholar
  3. 3.
    Francois RJ. Microradiographic study of the intervertebral bridges in ankylosing spondylitis and in the normal sacrum. Ann Rheum Dis 1965; 24:481–9.PubMedGoogle Scholar
  4. 4.
    de Vlam K, Mielants H, Verstaete KL et al. The zygapophyseal joint determines morphology of the enthesophyte. J Rheumatol 2000; 27:1732–9.PubMedGoogle Scholar
  5. 5.
    Appel H, Kuhne M, Spiekermann S et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845–51.PubMedGoogle Scholar
  6. 6.
    Francois RJ, Gardner DL, Degrave EJ et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000; 43:2011–24.PubMedGoogle Scholar
  7. 7.
    Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499–505.PubMedGoogle Scholar
  8. 8.
    Appel H, Kuhne M, Spiekermann S et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006; 54:1805–13.PubMedGoogle Scholar
  9. 9.
    Baeten D, Demetter P, Cuvelier C et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59:945–53.PubMedGoogle Scholar
  10. 10.
    Kruithof E, Baeten D, De Rycke L et al. Synovial histopathology of psoriatic arthritis, both oligo-and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7:R569–80.PubMedGoogle Scholar
  11. 11.
    Smeets TJ, Dolhain RJ, Breedveld FC et al. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998; 186:75–81.PubMedGoogle Scholar
  12. 12.
    van Kuijk AW, Reinders-Blankert P, Smeets TJ et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65:1551–7.PubMedGoogle Scholar
  13. 13.
    Cunnane G, Bresnihan B, FitzGerald O. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis Rheum 1998; 41:180–2.PubMedGoogle Scholar
  14. 14.
    Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409:198–201.PubMedGoogle Scholar
  15. 15.
    Baeten D, Kruithod E, De Rycke L et al. Infiltration of the synovival membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005; 7:R359–69.PubMedGoogle Scholar
  16. 16.
    Kruithof E, De Rycke L, Vandooren B et al. OMERACT Special Interest Group on Synovial Analysis in Clinical Trials. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006; 54:1795–804.PubMedGoogle Scholar
  17. 17.
    Reece RJ, Canete JD, Parsons WJ et al. Distinct vascular patterns of early synovitis in psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999; 42:1481–4.PubMedGoogle Scholar
  18. 18.
    Canete JD, Rodriguez JR, Salvador G et al. Diagnostic usefulness of synovial vascular morphology in chronic arthritis. A systematic survey of 100 cases. Semin Arthritis Rheum 2003; 32:378–87.PubMedGoogle Scholar
  19. 19.
    Francois RJ, Braun J, Khan MA. Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. Curr Opin Rheumatol 2001; 13:255–64.PubMedGoogle Scholar
  20. 20.
    McGonagle D, Marzo-Ortega H, O’Connor P et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002; 61:534–7.PubMedGoogle Scholar
  21. 21.
    Laloux L, Voisin MC, Allain J et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60:316–21.PubMedGoogle Scholar
  22. 22.
    Said-Nahal R, Miceli-Richard C, D’Agostino MA et al. Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis Rheum 2001; 45:478–84.PubMedGoogle Scholar
  23. 23.
    Calin A, Marder A, Marks S et al. Familial aggregation of Reiter’s syndrome and ankylosing spondylitis: a comparative study. J Rheumatol 1984; 11:672–7.PubMedGoogle Scholar
  24. 24.
    Gossec L, van der Heijde D, Melian A et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64:1563–7.PubMedGoogle Scholar
  25. 25.
    Braun J, Zochling J, Baraliakos X et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65:1147–53.PubMedGoogle Scholar
  26. 26.
    Clegg DO, Reda DJ, Weisman MH et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2004–12.PubMedGoogle Scholar
  27. 27.
    Vandooren B, Kruithof E, Yu DT et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50:2942–53.PubMedGoogle Scholar
  28. 28.
    Maksymowych WP, Landewe R, Conner-Spady B et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56:1846–53.PubMedGoogle Scholar
  29. 29.
    Brophy S, Mackay K, Al-Saidi A et al. The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 2002; 29:1236–43.PubMedGoogle Scholar
  30. 30.
    Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218–27.PubMedGoogle Scholar
  31. 31.
    van der Linden S. Spondyloarthropathies. In: Kelley, Harris, Ruddy and Sledge. Textbook of Rheumatology, 5th Ed. 1997; 969–82.Google Scholar
  32. 32.
    Polzer K, Schett G, Zwerina J. The lonely death: chondrocyte apoptosis in TNF-induced arthritis. Autoimmunity 2007; 40:333–6.PubMedGoogle Scholar
  33. 33.
    Zwerina J, Redlich K, Polzer K et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104:11742–7.PubMedGoogle Scholar
  34. 34.
    Redlich K, Hayer S, Ricci R et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110:1419–27.PubMedGoogle Scholar
  35. 35.
    Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13:156–63.PubMedGoogle Scholar
  36. 36.
    Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689–99.PubMedGoogle Scholar
  37. 37.
    Lam J, Takeshita S, Barker JE et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481–8.PubMedGoogle Scholar
  38. 38.
    Wei S, Kitaura H, Zhou P et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282–90.PubMedGoogle Scholar
  39. 39.
    Rountree RB, Schoor M, Chen H et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol 2004; 2:e355.PubMedGoogle Scholar
  40. 40.
    Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005; 115:1571–9.PubMedGoogle Scholar
  41. 41.
    van Beuningen HM, Glansbeek HL, van der Kraan PM et al. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage 1998; 6:306–17.PubMedGoogle Scholar
  42. 42.
    van Beuningen HM, van der Kraan PM, Arntz OJ et al. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 1994; 71:279–90.PubMedGoogle Scholar
  43. 43.
    Valencia X, Higgins JM, Kiener HP et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004; 200:1673–9.PubMedGoogle Scholar
  44. 44.
    Lee DM, Kiener HP, Agarwal SK et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315:1006–10.PubMedGoogle Scholar
  45. 45.
    Vandooren B, Cantaert T, van Lierop MJ et al. Melanoma Inhibitory Activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Submitted for publication.Google Scholar
  46. 46.
    Vandooren B, Cantaert T, Noordenbos T et al. The abundant synovial expression of the RANK-RANKL-OPG system in peripheral spondyloarthritis is partially disconnected from inflammation. Arthritis Rheum. In press.Google Scholar
  47. 47.
    Ritchlin CT, Haas-Smith SA, Li P et al. Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821–31.PubMedGoogle Scholar
  48. 48.
    Lories RJ, Derese I, Ceuppens JL et al. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 2003; 48:2807–18.PubMedGoogle Scholar
  49. 49.
    Glansbeek HL, van Beuningen HM, Vitters EL et al. Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1 alpha effects on proteoglycan synthesis and content. Arthritis Rheum 1997; 40:1020–8.PubMedGoogle Scholar
  50. 50.
    Chen Y, Whetstone HC, Youn A et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem 2007; 282:526–33.PubMedGoogle Scholar
  51. 51.
    Ribbens C, Martin y Porras M, Franchimont N et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002; 61:161–6.PubMedGoogle Scholar
  52. 52.
    Chen CH, Lin KC, Yu DT et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 2006; 45:414–20.PubMedGoogle Scholar
  53. 53.
    Yang C, Gu J, Rihl M et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004; 51:691–9.PubMedGoogle Scholar
  54. 54.
    Kim TH, Stone M, Payne U et al. Inman Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005;52:885–91.PubMedGoogle Scholar
  55. 55.
    Maksymowych WP, Poole AR, Hiebert L et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005; 32:1911–7.PubMedGoogle Scholar
  56. 56.
    Olsen AK, Sondergaard BC, Byrjalsen I et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007; 15:335–42.PubMedGoogle Scholar
  57. 57.
    Grisar J, Bernecker PM, Aringer M et al. Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29:1430–6.PubMedGoogle Scholar
  58. 58.
    Woo JH, Lee HJ, Sung IH et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007; 34:1753–9.PubMedGoogle Scholar
  59. 59.
    Baeten D, Kruithof E, De Rycke L et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis bysynovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004; 50:2931–41.PubMedGoogle Scholar
  60. 60.
    Baeten D, Kruithof E, De Rycke L et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005; 7:R359–69.PubMedGoogle Scholar
  61. 61.
    Kruithof E, De Rycke L, Vandooren B et al. OMERACT Special Interest Group on Synovial Analysis in Clinical Trials. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis Arthritis Rheum 2006; 54:1795–804.PubMedGoogle Scholar
  62. 62.
    Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol 2006; 20:593–9.PubMedGoogle Scholar
  63. 63.
    Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology 2004; 126:1504–17.PubMedGoogle Scholar
  64. 64.
    Porcher R, Said-Nahal R, D’Agostino MA et al. Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. Arthritis Rheum 2005; 53:263–71.PubMedGoogle Scholar
  65. 65.
    de Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27:2860–5.PubMedGoogle Scholar
  66. 66.
    Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411:599–603.PubMedGoogle Scholar
  67. 67.
    Laukens D, Peeters H, Marichal D et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis 2005; 64:930–5.PubMedGoogle Scholar
  68. 68.
    Bjarnason I, Helgason KO, Geirsson AJ et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003; 125:1598–605.PubMedGoogle Scholar
  69. 69.
    Peeters H, Vander Cruyssen B, Mielants H et al. Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 2007; [Epub ahead of print].Google Scholar
  70. 70.
    Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461–3.PubMedGoogle Scholar
  71. 71.
    Capon F, Di Meglio P, Szaub J et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122:201–206.PubMedGoogle Scholar
  72. 72.
    Brown MA. Nature Genetics. In Press.Google Scholar
  73. 73.
    Mannon PJ, Fuss IJ, Mayer L et al. Anti-IL-12 Crohn’s Disease Study Group. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004; 351:2069–79.PubMedGoogle Scholar
  74. 74.
    Krueger GG, Langley RG, Leonardi C et al. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580–92.PubMedGoogle Scholar
  75. 75.
    De Vos M, Cuvelier C, Mielants H et al. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989; 96:339–44.PubMedGoogle Scholar
  76. 76.
    Demetter P, Van Huysse JA, De Keyser F et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol 2002; 198:517–22.PubMedGoogle Scholar
  77. 77.
    Becker C, Wirtz S, Blessing M et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003; 112:693–706.PubMedGoogle Scholar
  78. 78.
    Demetter P, De Vos M, Van Huysse JA et al. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005; 64:321–4.PubMedGoogle Scholar
  79. 79.
    Baeten D, Demetter P, Cuvelier CA et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002; 196:343–50.PubMedGoogle Scholar
  80. 80.
    Van Damme N, Elewaut D, Baeten D et al. Gut mucosal T-cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol 2001; 19:681–7.PubMedGoogle Scholar
  81. 81.
    Van Damme N, De Keyser F, Demetter P et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol 2001; 125:383–90.PubMedGoogle Scholar
  82. 82.
    Canete JD, Martinez SE, Farres J et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000; 59:263–8.PubMedGoogle Scholar
  83. 83.
    Baeten D, Van Damme N, Van den Bosch F et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001; 60:750–5.PubMedGoogle Scholar
  84. 84.
    Rudwaleit M, Siegert S, Yin Z et al. Low T-cell production of TNFalpha and IFN gamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60(1):36–42.PubMedGoogle Scholar
  85. 85.
    Baeten D, De Keyser F, Mielants H et al. Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 2002; 14:342–7.PubMedGoogle Scholar
  86. 86.
    May E, Marker-Hermann E, Wittig BM et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000; 119:1745–55.PubMedGoogle Scholar
  87. 87.
    Hammer RE, Maika SD, Richardson JA et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27 associated human disorders. Cell 1990; 30:1099–112.Google Scholar
  88. 88.
    Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359–64.PubMedGoogle Scholar
  89. 89.
    Breban M, Fernandez-Sueiro JL, Richardson JA et al. T-cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156:794–803.PubMedGoogle Scholar
  90. 90.
    Hacquard-Bouder C, Chimenti MS, Giquel B et al. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T-cells: selective impairment of costimulatory molecule engagement by mature HLA-B27. Arthritis Rheum 2007; 56:1478–89.PubMedGoogle Scholar
  91. 91.
    Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu-Rev Immunol 2002; 20:197–216.PubMedGoogle Scholar
  92. 92.
    Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725–34.PubMedGoogle Scholar
  93. 93.
    De Rycke L, Kruithof E, Vandooren B et al. Pathogenesis of spondyloarthritis: insights from synovial membrane studies. Curr Rheumatol Rep 2006; 8:275–82.PubMedGoogle Scholar
  94. 94.
    Liew FY, Xu D, Brint EK et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446–58.PubMedGoogle Scholar
  95. 95.
    Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78–83.PubMedGoogle Scholar
  96. 96.
    Mansell A, Smith R, Doyle SL et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006; 7:148–55.PubMedGoogle Scholar
  97. 97.
    Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350–4.PubMedGoogle Scholar
  98. 98.
    Boone DL, Turer EE, Lee EG et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5:1052–60.PubMedGoogle Scholar
  99. 99.
    Trompouki E, Hatzivassiliou E, Tsichritzis T et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424:793–6.PubMedGoogle Scholar
  100. 100.
    Yoshida H, Jono H, Kai H et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280:41111–21.PubMedGoogle Scholar
  101. 101.
    Inman RD, Rohekar S, Reena R et al. TLR2, but not TLR4, variants are associated with reactive arthritis. Poster presentation American College of Rheumatology meeting 2007.Google Scholar
  102. 102.
    De Rycke L, Vandooren B, Kruithof E et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005; 52:2146–58.PubMedGoogle Scholar
  103. 103.
    Watanabe T, Kitani A, Murray PJ et al. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006; 25:473–85.PubMedGoogle Scholar
  104. 104.
    Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987–95.PubMedGoogle Scholar
  105. 105.
    Kim KD, Zhao J, Auh S et al. Adaptive immune cells temper initial innate responses. Nat Med 2007; 13:1248–52PubMedGoogle Scholar
  106. 106.
    Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253–6.PubMedGoogle Scholar
  107. 107.
    Rimoldi M, Chieppa M, Salucci V et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005; 6:507–14.PubMedGoogle Scholar
  108. 108.
    Hart AL, Al-Hassi HO, Rigby RJ et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129:50–65.PubMedGoogle Scholar
  109. 109.
    Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849–61.PubMedGoogle Scholar
  110. 110.
    Elson CO, Cong Y, Weaver CT et al. Monoclonal anti-interleukin 23 reverses active colitis in a T-cell-mediated model in mice. Gastroenterology 2007; 132:2359–70.PubMedGoogle Scholar
  111. 111.
    Timms AE, Crane AM, Sims AM et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75:587–95.PubMedGoogle Scholar
  112. 112.
    Maksymowych WP, Rahman P, Reeve JP et al. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 2006; 54:974–85.PubMedGoogle Scholar
  113. 113.
    Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat Immunol 2007; 8:950–7.PubMedGoogle Scholar
  114. 114.
    Benjamin M, Toumi H, Suzuki D et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27 associated spondylarthritides and allied disorders. Arthritis Rheum 2007; 56:224–33.PubMedGoogle Scholar
  115. 115.
    Corps AN, Robinson AH, Movin T et al. Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy. Rheumatology 2006; 45:291–4.PubMedGoogle Scholar
  116. 116.
    Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223–33.PubMedGoogle Scholar
  117. 117.
    Dossumbekova A, Anghelina M, Madhavan S et al. Biomechanical signals inhibit IKK activity to attenuate NF-kappaB transcription activity in inflamed chondrocytes. Arthritis Rheum 2007; 56:3284–3296.PubMedGoogle Scholar
  118. 118.
    Agarwal S, Deschner J, Long P et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 2004; 50:3541–8.PubMedGoogle Scholar
  119. 119.
    Yang XO, Panopoulos AD, Nurieva R et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T-cells. J Biol Chem 2007; 282:9358–63.PubMedGoogle Scholar
  120. 120.
    Laitio P, Virtala M, Salmi M et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 1997; 27:1331–8.PubMedGoogle Scholar
  121. 121.
    Turner MJ, Sowders DP, DeLay ML et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005; 175:2438–48.PubMedGoogle Scholar
  122. 122.
    Tran TM, Dorris ML, Satumtira N et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006; 54:1317–27.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Bernard Vandooren
    • 1
  • Paul P. Tak
    • 2
  • Dominique Baeten
    • 3
  1. 1.Clinical Immunology and RheumatologyUniversity of AmsterdamGhentBelgium
  2. 2.Division of Clinical Immunology and RheumatologyDepartment of Internal MedicineAmsterdamThe Netherlands
  3. 3.Clinical Immunology and RheumatologyAcademic Medical Center/University of AmsterdamAmsterdamThe Netherlands

Personalised recommendations